Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week High – Time to Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) reached a new 52-week high during trading on Wednesday . The stock traded as high as $88.49 and last traded at $86.1950, with a volume of 314851 shares changing hands. The stock had previously closed at $83.92.

Analyst Ratings Changes

A number of equities analysts recently issued reports on DNTH shares. Truist Financial increased their target price on Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, March 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. Stifel Nicolaus set a $120.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, March 9th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a report on Monday, March 9th. Finally, Robert W. Baird upped their target price on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a report on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $117.30.

Dianthus Therapeutics Trading Up 2.1%

The stock has a market capitalization of $3.81 billion, a PE ratio of -20.90 and a beta of 1.56. The stock’s fifty day simple moving average is $61.76 and its 200-day simple moving average is $47.09.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings results on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The firm had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.40 million. As a group, analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Insider Activity at Dianthus Therapeutics

In related news, CAO Edward Carr sold 43,682 shares of Dianthus Therapeutics stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total transaction of $3,559,646.18. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marino Garcia sold 122,918 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total value of $10,016,587.82. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 200,430 shares of company stock valued at $16,332,702. 16.56% of the stock is owned by insiders.

Institutional Trading of Dianthus Therapeutics

Several hedge funds have recently added to or reduced their stakes in DNTH. Raymond James Financial Inc. bought a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at approximately $27,000. Parkside Financial Bank & Trust lifted its stake in Dianthus Therapeutics by 131.7% in the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock valued at $37,000 after purchasing an additional 540 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Dianthus Therapeutics in the fourth quarter valued at approximately $40,000. Russell Investments Group Ltd. bought a new position in Dianthus Therapeutics during the third quarter valued at $64,000. Finally, Tower Research Capital LLC TRC increased its position in Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after buying an additional 3,317 shares during the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.